Since Rallybio launched in 2018, the Connecticut-based company has been laser-focused on the development of “transformative therapeutics” for patients suffering from rare and ultra-rare diseases.
The leadership team, formed from former executives of Alexion Pharmaceuticals, all have experience working with the development of innovative therapeutics for rare diseases. With an extensive background in the field, the team, which includes Martin Mackay, Stephen Uden and Jeffrey Fryer, is entering 2022 with a steady sense of purpose around the mission of delivering those transformative therapeutics.